✦ LIBER ✦

Bevacizumab not cost effective in advanced ovarian cancer

✍ Scribed by Naik, Haladhara; Goswami, Ashok; Kim, Guinyun; Kim, Kwangsoo; Yang, Sung-Chul; Sahid, Muhammad; Zaman, Muhammad; Lee, Manwoo; Shin, Sung-Gyun; Cho, Moo-Hyun

Book ID: 121552685
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2014
Weight: 199 KB
Volume: 696
Category: Article
ISSN: 1173-5503
DOI: 10.1007/s40274-014-1030-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Consolidation paclitaxel is more cost-ef

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced ovarian cancer

✍ J. Lesnock; C. Farris; T. Krivak; K. Smith; M. Markman 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 303 KB

Bevacizumab + capecitabine not cost effe

Bevacizumab + capecitabine not cost effective in mCRC

✍ Ritter, M.; Mußhoff, O.; Odening, M. 📂 Article 📅 2013 🏛 Adis International Limited (now part of Wolters Kl ⚖ 111 KB

Consolidation paclitaxel is more cost-ef

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer

✍ Jamie L. Lesnock; Coreen Farris; Thomas C. Krivak; Kenneth J. Smith; Maurie Mark 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 344 KB

Cost-effectiveness of adding bevacizumab

Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer

✍ Mehta, Darshan A.; Hay, Joel W. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Bevacizumab shows activity in advanced r

Bevacizumab shows activity in advanced refractory epithelial ovarian cancer

📂 Article 📅 2005 🏛 Adis International Limited (now part of Wolters Kl ⚖ 151 KB

Bevacizumab in ovarian cancer

📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 88 KB